AbbVie Enters Strategic Alliance with iSTAR Medical for MINIject with Option to Acquire

July 20, 2022

AbbVie has entered into a strategic alliance with iSTAR Medical to further develop and commercialize the MINIject minimally invasive glaucoma surgery (MIGS) device. iSTAR will receive a $60M non-dilutive upfront payment and AbbVie holds an exclusive right to acquire iSTAR, with up to $475M of additional contingent payments tied to closing and milestones; iSTAR will remain independent until completion of its STAR‑V study.

Buyers
AbbVie
Targets
iSTAR Medical
Industry
Medical Devices
Location
Belgium
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.